FORT LAUDERDALE, FL — (Marketwired) — 10/20/14 — OmniComm Systems, Inc. (OTCQB: OMCM), a global leading provider of clinical data management technology, was selected by a top 10 pharmaceutical company to migrate its on-premise clinical data management technology to OmniCloud (OmniComm–s clinical cloud technology platform). This is part of an overarching corporate initiative to migrate all clinical development enterprise applications to the cloud. This is the largest initiative of its kind for OmniComm since the launch of OmniCloud in June of this year.
OmniCloud enables organizations to address key challenges in creating an integrated best-in-class clinical enterprise that makes it easier for clinical development organizations to realize the benefits of cloud implementation. OmniComm hosts and maintains the entire IT infrastructure, ensuring clinical data management technology is always running; data is secure, and product enhancements are rolled out in timely fashion. OmniComm–s robust, state-of-the art, compliant hosting environment was another critical factor in their selection process, as was OmniComm–s flexible approach to integrate JReview® and other companion third-party applications.
“The Pharmaceutical industry is moving swiftly to cloud technology, as it allows organizations to save costs, scale their business, and reap the benefits of new innovation at a much quicker pace,” said Ken Light, EVP of Transformation and Professional Services at OmniComm. “Our Transformation Services team is providing expert subject matter expertise and technology support to ensure a seamless migration of systems and data into our secure software-as-a-service (SaaS) cloud-based infrastructure.”
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world–s pharmaceutical; biotechnology; contract research organizations; diagnostic and device firms; and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit .
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company–s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company–s financial results can be found in the Company–s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
You must be logged in to post a comment Login